News | April 26, 2024
Merck 1Q 2024 sales up 9% to US$ 15.8 billion
Sales reflect continued strong growth in oncology and vaccines
Sales reflect continued strong growth in oncology and vaccines
Late-breaking data to be featured in an oral presentation at the American Association for Cancer Research (AACR) annual meeting on Monday, April 8 and highlighted as part of the official meeting press program
The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 21, 2024
Combination shows consistent benefit across prespecified post-progression outcomes
XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy in nonmetastatic castration-sensitive prostate cancer
Jemperli is the only immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapy
Decisions on the marketing authorization for Rystiggo in the European and Japanese markets are expected in Q1 of 2024
As Caeregen’s CDMO partner for CTR-107, Wacker Biotech will produce drug substance at its site in Halle, Germany, and complete clinical trial drug product production at its site in Amsterdam, the Netherlands
Application being reviewed under the FDA Project Orbis framework, which enables concurrent reviews among US, Australia, Canada, Switzerland, Singapore and United Kingdom health authorities
Olverembatinib is the first and only third-generation BCR-ABL inhibitor approved in China for the treatment of adult patients with tyrosine kinase inhibitors
Subscribe To Our Newsletter & Stay Updated
